BASIS OF PRESENTATION (Details Narrative) - USD ($)		3 Months Ended						9 Months Ended
BASIS OF PRESENTATION (Details Narrative) - USD ($)	Sep. 29, 2025	Sep. 30, 2025	Jun. 30, 2025	Mar. 31, 2025	Sep. 30, 2024	Jun. 30, 2024	Mar. 31, 2024	Sep. 30, 2025	Sep. 30, 2024	Dec. 31, 2024	Dec. 31, 2023
Restricted cash		$ 3,744,219						$ 3,744,219
Cash and cash equivalents		889,441						889,441		$ 315,105
Net cash used in operating activities								$ (3,851,273)	$ (3,883,215)
Convertible debt instrument, description								the Company entered into a Securities Purchase Agreement for the issuance of up to $300 million of senior secured convertible promissory notes, with an initial $8 million closing completed on August 6, 2025 (the ‘Initial Note’). The availability of these proceeds, primarily intended for digital asset acquisition and working capital, significantly improves the Company’s liquidity and alleviates substantial doubt regarding our ability to continue as a going concern for at least the next 12 months. The initial closing, amounting to $8 million, was completed on August 6, 2025, while additional tranches of up to $292 million may be issued in multiple subsequent closings, subject to the satisfaction of certain management and regulatory conditions as defined in the agreement. Under the terms of the initial note, the Company is entitled to receive an additional $2 million upon the effectiveness of the registration statement covering the shares issuable upon conversion of the Initial Note
Proceeds from issuance of stock under ATM program								$ 1,021,934	649,039
Stockholders' equity		23,134,884	$ 26,231,633	$ 25,951,711	$ 34,976,599	$ 32,119,574	$ 34,546,682	23,134,884	34,976,599	24,532,929	$ 36,043,028
Accumulated deficit		(123,021,330)						(123,021,330)		$ (114,022,275)
Working capital		(430,029)						(430,029)
Revenue		17,110,425			12,411,048			45,568,655	40,202,238
Net Loss		$ (5,352,890)	$ (2,828,068)	$ (818,097)	$ (2,182,534)	$ (2,590,711)	$ (1,866,690)	$ (8,999,055)	$ (6,639,935)
At-the-Market ("ATM") sales program
Issuance of stock under ATM program, shares	941,690							3,992,541
Proceeds from issuance of stock under ATM program	$ 1,021,933							$ 4,376,622

Cosmos Health Inc. 10-Q